New Trends in SARS-CoV-2 Variants and Vaccines: 2nd Edition

Dear Colleagues,

COVID-19 vaccines have proven to be an effective tool in preventing severe cases of COVID-19. Currently, four major vaccines have received approval from several countries. These vaccines are based on five different forms of technology:

1. Messenger ribonucleic acid (mRNA) vaccines - Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273).
2. Vector-based replication-deficient vaccines - chimpanzee adenoviruses (ChAdOx1 nCOV-19, also known as Vaxzevria by AstraZeneca) and human cells (Ad26.COV2 by Janssen).
3. Inactivated whole-virus vaccines - Sinovac (Coronavac) and Sinopharm (BBIBP-CorV).
4. Protein subunit vaccines - Novavax (Nuvaxovid and Covovax).
5. Bivalent vaccines - Pfizer-BioNTech/Comirnaty bivalent COVID-19 booster vaccine and the bivalent Moderna/Spikevax vaccine.

Individuals may experience differences in short- and long-term immune responses against SARS-CoV-2 infection after vaccination. The host genetics of the vaccine recipient and COVID-19 strains are important factors in evaluating the long-term sustainability of COVID-19 vaccines. In this Special Issue, we invite original research articles and reviews on topics including host genetic markers, immune response markers, vaccine efficacies against COVID-19 strains, population-based COVID-19 vaccine efficacy studies, and the side effects of COVID-19 vaccines. We look forward to receiving your contributions.

Dr. Seik-Soon Khor
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• COVID-19
• vaccines
• genetics
• genomes
• populations

• New Trends in SARS-CoV-2 Variants and Vaccines in Vaccines (8 articles)